New award for alendronate tablets with marlex pharmaceuticals, INC. Period of performance is 5/21/2026 - 5/20/2027.
Active Indefinite Delivery Contract Awarded Last action
- Contract number
- 36E79726D0016
- Awardee
-
Marlex Pharmaceuticals Inc. UEI VSSNJEFMPLB3
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- 6505--Alendronate Tablets Pre-Solicitation · 36E79725R0069 · Posted Oct 23, 2025
- Last date to order 41% complete
- IDV ceiling
- $4,350,222.40
- Award type
- Single award
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
The VA National Acquisition Center awarded a single-award indefinite delivery contract to Marlex Pharmaceuticals Inc. for Alendronate tablets, with a contract ceiling of $4,350,222.40, on May 21, 2026. The prime contractor is a minority-owned, Subcontinent Asian American-owned small disadvantaged business.
Performance occurs nationwide, with supplies distributed through the VA Pharmaceutical Prime Vendor Programs for use by the Department of Veterans Affairs, Bureau of Prisons, and Indian Health Service. The underlying solicitation (Request for Proposal 36E79725R0069) required offerors to supply Alendronate tablets in four configurations—35 mg tablets in 4-count and 12-count packages, and 70 mg tablets in 4-count and 12-count packages—with estimated annual usage ranging from 5,354 to 100,609 packages. The solicitation was issued in commercial item format under FAR Part 12.
The period of performance runs from May 21, 2026 through May 20, 2027, comprising a one-year base period with four pre-priced one-year option periods. NAICS code 325412 (Pharmaceutical Preparation Manufacturing) applies. The contract was structured as a full-and-open competitive procurement with no set-aside designation. A modification incorporating Section 5 of Executive Order 14398 (Clause 52.222-90, addressing DEI discrimination by federal contractors) was incorporated into the contract in April 2026.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 36E79726D0016?
36E79726D0016 was awarded to Marlex Pharmaceuticals Inc. by National Acquisition Center (Headquarters) on May 21, 2026.
How much is contract 36E79726D0016 worth?
36E79726D0016's own ceiling is $4,350,222.
Who can order from contract 36E79726D0016?
36E79726D0016 is a single award indefinite delivery contract.
Was contract 36E79726D0016 competed?
The extent of competition for 36E79726D0016 was full and open competition. The government received 2 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV